Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs

Brady L. Stein, MD
Published: Monday, Oct 30, 2017



Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

It is important that community oncologists realize these new guidelines exist, explains Stein. Whether a patient has primary myelofibrosis, essential thrombocythemia (ET), or polycythemia vera (PV), treatment is largely based on risk classification and symptom profiles. In patients with ET or PV, the risk classification is largely looking for patients who are at risk for thrombosis.

There also may be patients with MPNs who are not necessarily high risk, but still have robust symptoms. If a patient shows symptoms, observation is no longer an appropriate course of action, says Stein.


Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

It is important that community oncologists realize these new guidelines exist, explains Stein. Whether a patient has primary myelofibrosis, essential thrombocythemia (ET), or polycythemia vera (PV), treatment is largely based on risk classification and symptom profiles. In patients with ET or PV, the risk classification is largely looking for patients who are at risk for thrombosis.

There also may be patients with MPNs who are not necessarily high risk, but still have robust symptoms. If a patient shows symptoms, observation is no longer an appropriate course of action, says Stein.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x